Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $24
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $21 to $24.
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $21 to $24.